TME Pharma NV (XPAR:ALTME) Marketable Securities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TME Pharma NV Marketable Securities?

TME Pharma NV XPAR:ALTME +1.47% Marketable Securities is €0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. TME Pharma NV's Marketable Securities for the quarter that ended in Dec. 2025 was €0.00 Mil.

TME Pharma NV's annual Marketable Securities increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.01 Mil) but then declined from Dec. 2024 (€0.01 Mil) to Dec. 2025 (€0.00 Mil).

TME Pharma NV  (XPAR:ALTME) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

TME Pharma NV Marketable Securities Related Terms

TME Pharma NV Marketable Securities Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV Marketable Securities Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.00 0.00 0.01 0.00

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.00

TME Pharma NV Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
TME Pharma NV (XPAR:ALTME) has a Marketable Securities of €0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on TME Pharma NV and its competitors.
Is TME Pharma NV's Marketable Securities too high?
TME Pharma NV's current Marketable Securities is €0.00 Mil.
How does TME Pharma NV's Marketable Securities compare to VRTX and REGN?
TME Pharma NV's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.